Subcutaneous anifrolumab is superior to placebo in multiple systemic lupus erythematosus disease activity measures at 52 ...
Stocktwits on MSN
Why is ALVO stock rising pre-market today?
Alvotech stated that it designed the study to evaluate the safety, tolerability, and immunogenicity profiles of AVT80 and ...
Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...
The FDA delays approval AstraZeneca lupus drug Saphnelo for subcutaneous use, pending additional data; intravenous form remains available globally.
Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.
The company is working with the U.S. regulator to move forward with an updated application, adding a decision is expected in ...
The FDA rejected AstraZeneca's subcutaneous Saphnelo application, delaying U.S. approval until 2026, despite positive ...
February 2026 Update on US regulatory review of Saphnelo subcutaneous administration in systemic lupus erythematosus The US Food and Drug Administration (FDA) issued a complete response letter (CRL) ...
Please provide your email address to receive an email when new articles are posted on . DENVER — Subcutaneous administration of ocrelizumab showed similar safety and efficacy profiles to IV ...
AstraZeneca announces update on US regulatory review of Saphnelo subcutaneous administration in systemic lupus erythematosus: Cambridge, UK Wednesday, February 4, 2026, 16:00 Hrs ...
Many professionals report awareness, but few actively prescribe the self-administered injectable contraceptive DMPA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results